Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  HIV Infection

  Free Subscription

Articles published in Vaccine

Retrieve available abstracts of 68 articles:
HTML format

Single Articles

    November 2023
  1. MAN-LIK CHOI E, Abu-Baker Mustapher G, Omosa-Manyonyi G, Foster J, et al
    Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in
    Vaccine. 2023 Nov 17:S0264-410X(23)01257-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    October 2023
  2. CHECCHI M, Mesher D, Panwar K, Anderson A, et al
    The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females.
    Vaccine. 2023 Oct 9:S0264-410X(23)01162-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    September 2023
  3. REID MC, Mittler JE, Murphy JT, Stansfield SE, et al
    Evolution of HIV virulence in response to disease-modifying vaccines: A modeling study.
    Vaccine. 2023 Sep 13:S0264-410X(23)01027-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  4. TIEU HV, Karuna S, Huang Y, Sobieszczyk ME, et al
    Safety and immunogenicity of a recombinant oligomeric gp145 subtype C Env protein (gp145 C.6980) HIV vaccine candidate in healthy, HIV-1-uninfected adult participants in the US.
    Vaccine. 2023 Sep 5:S0264-410X(23)00877-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    August 2023
  5. DENG L, Tapper K, Thosar D, Goeman E, et al
    Use of adrenaline to manage suspected anaphylaxis following COVID-19 vaccination: An Australian retrospective cohort study.
    Vaccine. 2023 Aug 24:S0264-410X(23)00956-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  6. CAMPBELL J, Kaur A, Gamino D, Benoit E, et al
    Individual and structural determinants of COVID-19 vaccine uptake in a marginalized community in the United States.
    Vaccine. 2023 Aug 5:S0264-410X(23)00923-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  7. IZULLA P, Wagai JN, Akelo V, Ombeva A, et al
    Vaccine safety surveillance in Kenya using GAIA standards: A feasibility assessment of existing national and subnational research and program systems.
    Vaccine. 2023 Aug 5:S0264-410X(23)00906-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    June 2023
  8. LIU Z, Pang C, Deng Y, Guo C, et al
    Humoral immune response following the inactivated quadrivalent influenza vaccination among HIV-infected and HIV-uninfected adults.
    Vaccine. 2023 Jun 30:S0264-410X(23)00616-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  9. TURLEY CB, Tables L, Fuller T, Sanders LJ, et al
    Modifiers of COVID-19 vaccine efficacy: Results from four COVID-19 prevention network efficacy trials.
    Vaccine. 2023 Jun 23:S0264-410X(23)00755-7. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  10. SINGH A, Boggiano C, Eller MA, Maciel M Jr, et al
    Optimizing the Immunogenicity of HIV Vaccines by Adjuvants - NIAID Workshop Report.
    Vaccine. 2023 Jun 16:S0264-410X(23)00694-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  11. MUNOZ FM, Posavad CM, Richardson BA, Badell ML, et al
    COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
    Vaccine. 2023 Jun 13:S0264-410X(23)00698-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  12. TINGGAARD M, Slotved HC, Jorgensen CS, Kronborg G, et al
    Predictors of serological non-response to the 13-valent pneumococcal conjugate vaccine followed by the 23-valent polysaccharide vaccine among adults living with HIV.
    Vaccine. 2023 Jun 12:S0264-410X(23)00686-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    May 2023
  13. CHOI Y, Lee GS, Li S, Lee JW, et al
    Hepatitis B vaccine delivered by microneedle patch: Immunogenicity in mice and rhesus macaques.
    Vaccine. 2023 May 11:S0264-410X(23)00524-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    April 2023
  14. KOEN AL, Izu A, Baillie V, Kwatra G, et al
    Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
    Vaccine. 2023 Apr 27:S0264-410X(23)00483-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  15. ROPER RL, Garzino-Demo A, Del Rio C, Brechot C, et al
    Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.
    Vaccine. 2023 Apr 21:S0264-410X(23)00393-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  16. KOLAKOWSKA A, Brichler S, Delagreverie H, Marin J, et al
    Cross sectional survey of Varicella-Zoster virus and measles seropositivity in people living with HIV in a Parisian suburb and a review of current immunization guidelines.
    Vaccine. 2023 Apr 19:S0264-410X(23)00351-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    March 2023
  17. WILSON GJ, Rodriguez B, Li SS, Allen M, et al
    Cellular and humoral responses to an HIV DNA prime by electroporation boosted with recombinant vesicular stomatitis virus expressing HIV subtype C Env in a randomized controlled clinical trial.
    Vaccine. 2023 Mar 17:S0264-410X(23)00262-1. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  18. CLAY PA, Thompson TD, Markowitz LE, Ekwueme DU, et al
    Updated estimate of the annual direct medical cost of screening and treatment for human papillomavirus associated disease in the United States.
    Vaccine. 2023 Mar 10:S0264-410X(23)00184-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  19. SRIVASTAV A, Lu PJ, Amaya A, Dever JA, et al
    Prevalence of influenza-specific vaccination hesitancy among adults in the United States, 2018.
    Vaccine. 2023 Mar 10:S0264-410X(23)00255-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  20. GILBERT M, Ablona A, Chang HJ, Grennan T, et al
    Uptake of Mpox vaccination among transgender people and gay, bisexual and other men who have sex with men among sexually-transmitted infection clinic clients in Vancouver, British Columbia.
    Vaccine. 2023 Mar 7:S0264-410X(23)00229-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    February 2023
  21. BAKHSHIZADEH GASHTI A, Chahal PS, Gaillet B, Garnier A, et al
    Purification of recombinant vesicular stomatitis virus-based HIV vaccine candidate.
    Vaccine. 2023 Feb 24:S0264-410X(23)00201-3. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  22. FANTINATO FFST, Wachira VK, Porto VBG, Peixoto HM, et al
    Factors associated with yellow fever vaccine failure: A systematic literature review.
    Vaccine. 2023 Feb 23:S0264-410X(23)00133-0. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  23. KABIR SULAIMAN S, Sale Musa M, Isma'il Tsiga-Ahmed F, Muhammad Dayyab F, et al
    COVID-19 vaccine hesitancy among people living with HIV in a low-resource setting: A multi-center study of prevalence, correlates and reasons.
    Vaccine. 2023 Feb 23:S0264-410X(23)00199-8. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  24. FORD A, Hwang A, Mo AX, Baqar S, et al
    Meeting Summary: Global Vaccine and Immunization Research Forum, 2021.
    Vaccine. 2023 Feb 18:S0264-410X(23)00163-9. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

  25. CAMPMAN SL, van Rossem G, Boyd A, Coyer L, et al
    Intent to vaccinate against SARS-CoV-2 and its determinants across six ethnic groups living in Amsterdam, the Netherlands: A cross-sectional analysis of the HELIUS study.
    Vaccine. 2023 Feb 13:S0264-410X(23)00165-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    January 2023
  26. STRATHDEE SA, Abramovitz D, Vera CF, Artamonova I, et al
    Predictors of COVID-19 vaccine uptake among people who inject drugs.
    Vaccine. 2023 Jan 23:S0264-410X(23)00063-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available

    December 2022
  27. BURROWS H, Antillon M, Gauld JS, Kim JH, et al
    Comparison of model predictions of typhoid conjugate vaccine public health impact and cost-effectiveness.
    Vaccine. 2022 Dec 29:S0264-410X(22)01557-2. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available

  28. ZUBKOVA I, Zhao Y, Cui Q, Kachko A, et al
    Assessing the impact of hepatitis B immune globulin (HBIG) on responses to hepatitis B vaccine during co-administration.
    Vaccine. 2022 Dec 29:S0264-410X(22)01590-0. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available

  29. TRACEY G, Olivia B, Jean M, Megan H, et al
    Why does gender matter for immunization?
    Vaccine. 2022 Dec 10:S0264-410X(22)01495-5. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available

    November 2022
  30. SULLIVAN KM, Farraye FA, Winthrop KL, Willer DO, et al
    Safety and efficacy of recombinant and live herpes zoster vaccines for prevention in at-risk adults with chronic diseases and immunocompromising conditions.
    Vaccine. 2022 Nov 29:S0264-410X(22)01329-9. doi: 10.1016/j.vaccine.2022.
    PubMed     Abstract available

  31. FIX J, Vielot NA, Lund JL, Weber DJ, et al
    Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Vaccine. 2022 Nov 14. pii: S0264-410X(22)01347.
    PubMed     Abstract available

  32. CAREY KA, Newman LM, Spicknall IH
    Estimating the population level impact of a gonococcal vaccine candidate: Predictions from a simple mathematical model.
    Vaccine. 2022 Nov 1. pii: S0264-410X(22)01291.
    PubMed     Abstract available

    October 2022
  33. GILLES C, Rozenberg S, Buxant F, Manigart Y, et al
    HPV genotyping in biopsies of HSIL and invasive cervical cancers in women living with HIV: A cohort- and a nested -case control study.
    Vaccine. 2022 Oct 31. pii: S0264-410X(22)01288.
    PubMed     Abstract available

  34. SHU Y, Yu Y, Ji Y, Zhang L, et al
    Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45 years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial.
    Vaccine. 2022 Oct 22. pii: S0264-410X(22)01281.
    PubMed     Abstract available

  35. STONER MCD, Tweedy D, Comello MGL, Toval C, et al
    Using narratives to inform the development of a digital health intervention related to COVID-19 vaccination in Black young adults in Georgia, North Carolina and Alabama.
    Vaccine. 2022 Oct 20. pii: S0264-410X(22)01286.
    PubMed     Abstract available

  36. ODIO CD, Katzelnick LC
    'Mix and Match' vaccination: Is dengue next?
    Vaccine. 2022 Oct 1. pii: S0264-410X(22)01101.
    PubMed     Abstract available

    September 2022
  37. MANJATE F, Quinto L, Chirinda P, Acacio S, et al
    Impact of rotavirus vaccination on diarrheal hospitalizations in children younger than 5 years of age in a rural southern Mozambique.
    Vaccine. 2022 Sep 30. pii: S0264-410X(22)01158.
    PubMed     Abstract available

  38. MUES KE, Kirk B, Patel DA, Gelman A, et al
    Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States.
    Vaccine. 2022 Sep 23. pii: S0264-410X(22)01120.
    PubMed     Abstract available

    July 2022
  39. OSTROPOLETS A, Shoener Dunham L, Johnson KD, Liu J, et al
    Pneumococcal vaccination coverage among adults newly diagnosed with underlying medical conditions and regional variation in the U.S.
    Vaccine. 2022 Jul 5. pii: S0264-410X(22)00837.
    PubMed     Abstract available

  40. XIRIDOU M, Adam P, Meiberg A, Visser M, et al
    The impact of the COVID-19 pandemic on hepatitis B virus vaccination and transmission among men who have sex with men: A mathematical modelling study.
    Vaccine. 2022 Jul 4. pii: S0264-410X(22)00847.
    PubMed     Abstract available

    June 2022
  41. UFFMAN EA, Li SH, Chen JL, Allen N, et al
    Kinetics of pneumococcal antibodies among HIV-exposed, uninfected infants in Botswana.
    Vaccine. 2022 Jun 27. pii: S0264-410X(22)00828.
    PubMed     Abstract available

  42. CASAGRANDE TZ, Costa-Rocha IAD, Gavi MBRO, Miyamoto ST, et al
    Previous biological therapy and impairment of the IFN-gamma/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis.
    Vaccine. 2022 Jun 18. pii: S0264-410X(22)00703.
    PubMed     Abstract available

  43. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    PubMed     Abstract available

  44. ARAUJO BC, Simakawa R, Munhoz LG, Carmo FB, et al
    Rubella antibodies in vertically and horizontally HIV-infected young adults vaccinated early in life and response to a booster dose in those with seronegative results.
    Vaccine. 2022 Jun 15. pii: S0264-410X(22)00774.
    PubMed     Abstract available

  45. FOLEGATTI PM, Jenkin D, Morris S, Gilbert S, et al
    Vaccines based on the replication-deficient simian adenoviral vector ChAdOx1: Standardized template with key considerations for a risk/benefit assessment.
    Vaccine. 2022 Jun 14. pii: S0264-410X(22)00755.
    PubMed     Abstract available

  46. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    PubMed     Abstract available

  47. WROTNIAK BH, Garrett M, Baron S, Sojar H, et al
    Antibody dependent cell cytotoxicity is maintained by the unmutated common ancestor of 6F5, a Gp41 conformational epitope targeting antibody that utilizes heavy chain VH1-2.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00719.
    PubMed     Abstract available

  48. WYNBERG E, Han AX, Boyd A, van Willigen HDG, et al
    The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): A prospective cohort study.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00748.
    PubMed     Abstract available

    May 2022
  49. MOSS P, Berenbaum F, Curigliano G, Grupper A, et al
    Benefit-risk evaluation of COVID-19 vaccination in special population groups of interest.
    Vaccine. 2022 May 27. pii: S0264-410X(22)00682.
    PubMed     Abstract available

  50. KITCHEN M, Leierer G, Kistner O, Wodal W, et al
    High seroprotection rates and geometric mean titre increases after repeated annual influenza vaccinations in a cohort of HIV-infected adults in Austria.
    Vaccine. 2022 May 20. pii: S0264-410X(22)00575.
    PubMed     Abstract available

  51. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Increases in human papillomavirus vaccine coverage over 12 months among a community-recruited cohort of gay, bisexual, and other men who have sex with men in Canada.
    Vaccine. 2022 May 13. pii: S0264-410X(22)00590.
    PubMed     Abstract available

  52. CUMMINS NW, Badley AD
    Could proteasome inhibition improve therapeutic vaccine response in HIV?
    Vaccine. 2022 May 12. pii: S0264-410X(22)00578.

  53. NAULT L, Marchitto L, Goyette G, Tremblay-Sher D, et al
    Covid-19 vaccine immunogenicity in people living with HIV-1.
    Vaccine. 2022 May 5. pii: S0264-410X(22)00543.
    PubMed     Abstract available

  54. NANTANEE R, Aikphaibul P, Jaru-Ampornpan P, Sodsai P, et al
    Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac.
    Vaccine. 2022 May 2. pii: S0264-410X(22)00521.
    PubMed     Abstract available

    April 2022
  55. PERCIACCANTE A, Asensi V, Cucu AI, Charlier P, et al
    War, pandemic and vaccination - Upcoming health problems by the refugee wave in Europe?
    Vaccine. 2022 Apr 23. pii: S0264-410X(22)00465.

    March 2022
  56. NANTHAPISAL S, Puthanakit T, Jaru-Ampornpan P, Nantanee R, et al
    A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Vaccine. 2022 Mar 24. pii: S0264-410X(22)00336.
    PubMed     Abstract available

  57. ISHII H, Nakamura-Hoshi M, Shu T, Matano T, et al
    Sendai virus particles carrying target virus glycoproteins for antibody induction.
    Vaccine. 2022 Mar 16. pii: S0264-410X(22)00273.
    PubMed     Abstract available

    February 2022
  58. QUITIAN LM, Rodriguez-Martinez CE, Sossa-Briceno MP, Cortes JA, et al
    Disease burden and vaccination priorities in Colombia.
    Vaccine. 2022 Feb 15. pii: S0264-410X(22)00029.
    PubMed     Abstract available

  59. KOCHHAR S, Barreira D, Beattie P, Cavaleri M, et al
    Building the concept for WHO Evidence Considerations for Vaccine Policy (ECVP): Tuberculosis vaccines intended for adults and adolescents as a test case.
    Vaccine. 2022 Feb 11. pii: S0264-410X(21)01395.
    PubMed     Abstract available

    January 2022
  60. PANWAR K, Godi A, Cocuzza CE, Andrews N, et al
    Binding antibody levels to vaccine (HPV6/11/16/18) and non-vaccine (HPV31/33/45/52/58) HPV antigens up to 7 years following immunization with either Cervarix(R) or Gardasil(R) vaccine.
    Vaccine. 2022 Jan 31. pii: S0264-410X(22)00075.
    PubMed     Abstract available

    December 2021
  61. RIBEIRO SP, De Moura Mattaraia VG, Almeida RR, Valentine EJG, et al
    A promiscuous T cell epitope-based HIV vaccine providing redundant population coverage of the HLA class II elicits broad, polyfunctional T cell responses in nonhuman primates.
    Vaccine. 2021 Dec 24. pii: S0264-410X(21)01550.
    PubMed     Abstract available

  62. FACK C, Wood R, Hatherill M, Cobelens F, et al
    The impact of a change in infant BCG vaccination policy on adolescent TB incidence rates: A South African population-level cohort study.
    Vaccine. 2021 Dec 3. pii: S0264-410X(21)01488.
    PubMed     Abstract available

    November 2021
  63. ZOU X, He J, Zheng J, Liang M, et al
    Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients.
    Vaccine. 2021 Nov 29. pii: S0264-410X(21)01532.
    PubMed     Abstract available

  64. BLAIN AE, Reese HE, Marjuki H, Topaz N, et al
    Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine - United States, 2014-2018.
    Vaccine. 2021 Nov 18. pii: S0264-410X(21)01480.
    PubMed     Abstract available

    October 2021
  65. MALTEZOU HC, Panagopoulos P, Sourri F, Giannouchos TV, et al
    COVID-19 vaccination significantly reduces morbidity and absenteeism among healthcare personnel: A prospective multicenter study.
    Vaccine. 2021 Oct 30. pii: S0264-410X(21)01387.
    PubMed     Abstract available

    September 2021
  66. KHAIMOVA R, Fischetti B, Cope R, Berkowitz L, et al
    Serological response with Heplisav-B(R) in prior Hepatitis B vaccine non-responders living with HIV.
    Vaccine. 2021 Sep 29. pii: S0264-410X(21)01251.
    PubMed     Abstract available

  67. LI L, Hessell AJ, Kong XP, Haigwood NL, et al
    A large repertoire of B cell lineages targeting one cluster of epitopes in a vaccinated rhesus macaque.
    Vaccine. 2021;39:5607-5614.
    PubMed     Abstract available

    August 2021
  68. LEWIN BJ, Rodriguez J, Yang SJ, Tartof SY, et al
    Predictors of hepatitis A immunity in adults in California in order to better utilize hepatitis A vaccine.
    Vaccine. 2021 Aug 25. pii: S0264-410X(21)01104.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.